Table 1. Patients’ characteristics.
| Variables | Study population (n=103) | Control population (n=101) | P value* |
|---|---|---|---|
| Gender | 0.407 | ||
| Male | 64 (62.1%) | 57 (56.4%) | |
| Female | 39 (37.9%) | 44 (43.6%) | |
| Age (years; range) | 69.3 (42.1–84.9) | 69.8 (30.4–87.6) | 0.767 |
| Smoking status | |||
| Never | 17 (16.5%) | 28 (27.7%) | 0.053 |
| Former and current | 86 (83.5%) | 73 (72.3%) | |
| ECOG PS | |||
| 0 | 26 (25.2%) | 31 (30.7%) | 0.458 |
| ≥1 | 77 (74.8%) | 70 (69.3%) | |
| Weight loss | 19 (18.4%) | 21 (20.8%) | 0.622 |
| Histology | 0.391 | ||
| Adenocarcinoma | 80 (77.7%) | 80 (79.2%) | |
| Squamous cell carcinoma | 20 (19.4%) | 21 (20.8%) | |
| NOS carcinoma | 2 (1.9%) | 0 (0.0%) | |
| Sarcomatoid carcinoma | 1 (1.0%) | 0 (0.0%) | |
| PD-L1 test performed | 95 (92.2%) | 88 (87.1%) | 0.394 |
| PD-L1 positive | |||
| Cut-off TPS ≥1% | 45 (47.4%) | 39 (44.3%) | 0.679 |
| Cut-off TPS ≥50% | 31 (32.6%) | 10 (11.4%) | 0.001 |
| Number of metastatic sites | 0.377 | ||
| 1 | 39 (37.9%) | 49 (48.5%) | |
| 2 | 39 (37.9%) | 33 (32.7%) | |
| ≥3 | 25 (24.2%) | 19 (18.8%) | |
| Sites of metastases | |||
| Extrathoracic | 52 (50.5%) | 50 (49.5%) | 0.933 |
| Liver | 15 (14.6%) | 11 (10.9%) | 0.415 |
| Bone | 29 (28.2%) | 26 (25.7%) | 0.698 |
| KRAS alteration | 22 (21.3%) | 26 (25.7%) | 0.364 |
| TP53 alteration | 53 (51.5%) | 41 (40.6%) | 0.200 |
| STK11 alteration | 9 (8.7%) | 10 (9.9%) | 0.775 |
| KRAS/STK11 co-mutation | 3 (2.9%) | 6 (5.9%) | 0.292 |
| STK11/TP53 co-mutation | 7 (6.8%) | 4 (3.9%) | 0.370 |
| TP53/KRAS co-mutation | 9 (8.7%) | 14 (13.8%) | 0.247 |
| KRAS/STK11/TP53 co-mutation | 2 (1.9%) | 2 (2.0%) | 0.325 |
*, statistical evaluation of variables’ distribution between the populations. Chi-squared test and Mann-Whitney were used as appropriate.